SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?


To: Julius Wong who wrote (157604)5/8/2020 11:19:27 PM
From: TobagoJack  Read Replies (1) | Respond to of 217547
 
Re <<What happens if a coronavirus vaccine is never developed? It has happened before>>

(1) for discussion's sake, suppose for a moment that the virus becomes a perennial and that a vaccine does not happen within 10 years, effectively a century for practical purposes, and likely beyond the planning horizon of anyone who makes plans, then what?

(1a) At the personal level, life less fun by some number between negative negative 89 - 99% except for loners, and for them, a toss up, between happy lonesomeness and draconian regime of annual outpour of walkers in the sun, assuming we do not have the worst case where the virus is not diminished by summers;

(1b) At the organisational level such as a church or an association, would have captive audience whenever they are not binging on Netflix (by the way, I am told "Trotsky" is an excellent Russian production on Netflix)

(1c) At the corporate level, meetings may become more efficient, by way of more productive, and cheeper, unless folks use the opportunity as escape from being alone, but the point of the meetings may be lessened as customers in hiding. Very difficult to plan another Big Mac Happy Meal promotion and such.

(1d) At the municipality level, taxes have to be lowered as folks can no longer pay, unless sustained bailouts happen irrespective of sustainability. Roads do not have to be maintained and schools cannot be physically opened, in the worst case that the virus flair is not only perennial, on clockwork, evolving, and immunity only works for the last virus caught

(1e) At the nation-state level, for the ones that practice universal electioneering, difficult, as people contact cut back, and priorities change, from trade wars and such to "what are you doing to return my life";

and for the nation-states practicing other styles of governance, easier, as the vector points to everything easier, cashless, full-view camera networks, social tracking, etc etc

(1f) At the multi-nations level, same same, except even more pointless for some projects, and more urgent for other projects, priorities defined by available budget and true imperative

(1g) For the monetary space, the issue becomes which persons, entities, and nations are sustainable in the neo-verse of new reality. Maybe nothing or that everything altered.

(2) Am scheduled for a social gathering for tomorrow (Sunday), a beach walk plus a two-family (altogether 4 of us and 2 of them) lunch, and as wine cannot be sold, a wine merchant shall give us a bottle, for cooking purpose. We have never scheduled beach walk before.

(3) In the meantime, the vector seems to be accelerating us toward unfamiliar territory, as if we are being bum-rushed into a vortex-ing negative space, where our positive bias is blackhole gravity shredded

cannot say whether good or bad, and am only sure the space is unfamiliar.

generally pause before entering unfamiliar, but under the circumstances, no pause possible, just bum-rushing.

even as there are folks still waiting for positive rate hikes, and thinking they are right.

bloomberg.com

Traders Are Baffled Why the Futures Market Is Pricing in Negative Rates

Vivien Lou Chen8 May 2020, 22:10 GMT+2
The futures market is again pricing in the possibility of the U.S. joining Europe and Japan with negative rates, catching money managers, traders and analysts off guard.

Expectations for the timing of below-zero rates -- as shown by contracts on the Fed funds rate -- shifted to the middle of 2021 after earlier indicating this scenario as soon as December amid dour jobs data that showed the worst employment downturn in U.S. history. But investors are still trying to figure out why markets have so rapidly embraced a theme that’s an anathema to many.

The timing is certainly odd. Despite continuing evidence of the economic damage caused by the coronavirus, investors have been embracing risk and volatility gauges are either falling or relatively stable in the past two days. In addition, Federal Reserve bank officials are still dismissing the notion of negative rates, while large investors don’t see the scenario happening and the consequences of any such move could be disastrous.



“I am surprised to see some of these expectations for negative rates so soon after the Fed has done so much, from significant asset purchase programs to zero rates and flooding the economy with liquidity,” said Larry Milstein, head of government debt trading at R.W. Pressprich & Co. in New York. “I would have thought that the market would wait to see how this all plays out, yet some investors think the Fed doesn’t have many more levers left.”

However, record-low yields are pointing to an undercurrent of worry in the market, with Scott Minerd, global chief investment officer of Guggenheim Partners, saying Friday that declining Treasury yields indicate negative rates could soon be here. Plus recent dramatic falls in one-month and three-month London interbank offered rates, on top of an influx of cash into money-market funds, may have prompted reluctant traders to begin fretting about the possibility of ever lower rates and to move up those expectations, even if only to hedge the risk, according to Jim Vogel, who manages fixed-income strategy at FHN Financial Capital Markets.

Still others see a litany of other possible reasons behind the market’s thinking that range from technical factors, such as stop-outs of short positions, to bank-hedging flows and -- more broadly -- growing deflation fears. Memories of April’s collapse in oil prices, due to too much supply and too little storage space, may have also offered an early glimpse into how low rates could get even for those holding out hope the Fed never goes there.

Billionaire Jeffrey Gundlach, co-founder of DoubleLine Capital, warning in a late Wednesday tweet about building pressures on fed funds to go negative along with the “fatal” consequences may have brought the expectations to the fore, according to Milstein.

Tony Farren, managing director at broker-dealer Mischler Financial in Stamford, Connecticut, expected it might take until August for the market to begin pricing in negative U.S. rates. In that late summer scenario, expectations for the economy to come “roaring back” instead fizzle out, inflation stays extreme low or turns into deflation, and Treasury yields across the board all make a run for zero.

“I’m still searching for a reason and see no reason why fed funds futures should have gone negative now,” he said. “I’m at a loss.”

Read More
Negative Fed Policy Rate Seen by Early 2021 in Futures Market

Negative Fed Rate May Boost Odds of Subzero Libor: Credit Suisse

Guggenheim’s Minerd Sees Clear Message on Looming Negative Rates

Fed Fund Futures Retreat After Powell Plans Speech on Economy


— With assistance by Alex Harris

Before it's here, it's on the Bloomberg Terminal.
LEARN MORE



To: Julius Wong who wrote (157604)5/8/2020 11:54:55 PM
From: TobagoJack  Read Replies (2) | Respond to of 217547
 
Maybe one of the mentioned will work, or others not noted

Good to know folks are working on it.

Am not even certain vaccine is necessary, but vaccines are not about necessary, but about options

bloomberg.com

A Look at the Most Promising Candidates for a Covid-19 Vaccine

Drug companies and university scientists are testing scores of possible inoculations.

More stories by Cristin Flanagan8 May 2020, 12:00 GMT+2



An engineer with an experimental Covid-19 vaccine at Sinovac Biotech’s facilities in Beijing on April 29.
Photographer: Nicolas Asfouri/AFP/Getty Images
LISTEN TO ARTICLE
From the U.S. to China to Germany, scientists are working around the clock to find a vaccine against the novel coronavirus. While experts caution that the process will take time—and that it’s not even a sure bet one can be found—some researchers say a vaccine could be ready for emergency use by the end of the year. The Trump administration has announced “ Operation Warp Speed” to have an inoculation ready as soon as possible.

Most of the programs are in their early stages, meaning the gold standard of data, clinical trials with “blinded” placebo and therapeutic groups, is still a ways off. In normal times, the process to approve a drug or vaccine is slow and painstaking. It can be accelerated but at the risk of incurring unforeseen harm. When rules are loosened in the desire to get a vaccine to market quickly, it’s important to cast a skeptical eye on too-good-to-be-true data. It’s also possible that more than one usable vaccine could emerge. In the polio epidemic of the 1950s, scientists developed two different kinds, first an injection and later oral drops, to help eradicate the disease.

One of These Vaccines Might End the Pandemic
Drug companies and university researchers are investigating about 100 experimental inoculations.
Data: World Health Organization, compiled by Bloomberg

Johnson & Johnson
Working on a $1 billion-plus effort with the U.S. government to test a vaccine, J&J plans to start human trials by September.

Inovio
Inovio kicked off its vaccine trial in April; the company is targeting larger studies this summer.

Moderna
The U.S. government has awarded the company almost $500 million in funding to develop and test its candidate. A patient trial is under way; early results could be available in late May or June.

Sinovac
The company says its inoculation can neutralize different strains of the virus.

CanSino Biologics
The Hong Kong-listed company worked alongside China’s military to develop a vaccine. It’s starting human trials in Wuhan.

Sanofi and GlaxoSmithKline
Sanofi is testing technology that’s already used in a flu shot, with Glaxo providing some of the ingredients. Patient trials could start in the second half of this year.

Imperial College London
Researchers have received funding for their vaccine project and aim to begin clinical trials in June.

China National Biotec
The Chinese state-owned drugmaker began conducting blinded, placebo-controlled human trials in April.

Oxford University and AstraZeneca
AstraZeneca has agreed to make an experimental inoculation developed by researchers at Oxford. Already being studied in humans, it could reach late-stage trials by the middle of the year.

BioNTech and Pfizer
The German and American duo launched clinical trials of its vaccine in the U.S. and Europe. If it’s successful and approved by regulators, the drugmaker could start distributing the shot on an emergency-use basis in the fall.

Read more: After Four Antibody Tests, I’m Still Not Sure I’ve Had Covid-19



To: Julius Wong who wrote (157604)5/9/2020 8:54:19 AM
From: Pogeu Mahone1 Recommendation

Recommended By
Julius Wong

  Respond to of 217547
 
Julius

thank you

youtube.com

What happens if a coronavirus vaccine is never developed? It has happened before

By Rob Picheta, CNN

Updated 0733 GMT (1533 HKT) May 4, 2020



London (CNN)As countries lie frozen in lockdown and billions of people lose their livelihoods, public figures are teasing a breakthrough that would mark the end of the crippling coronavirus pandemic: a vaccine.

But there is another, worst-case possibility: that no vaccine is ever developed. In this outcome, the public's hopes are repeatedly raised and then dashed, as various proposed solutions fall before the final hurdle.
Instead of wiping out Covid-19, societies may instead learn to live with it. Cities would slowly open and some freedoms will be returned, but on a short leash, if experts' recommendations are followed. Testing and physical tracing will become part of our lives in the short term, but in many countries, an abrupt instruction to self-isolate could come at any time. Treatments may be developed -- but outbreaks of the disease could still occur each year, and the global death toll would continue to tick upwards.

It's a path rarely publicly countenanced by politicians, who are speaking optimistically about human trials already underway to find a vaccine. But the possibility is taken very seriously by many experts -- because it's happened before. Several times.
"There are some viruses that we still do not have vaccines against," says Dr. David Nabarro, a professor of global health at Imperial College London, who also serves as a special envoy to the World Health Organization on Covid-19. "We can't make an absolute assumption that a vaccine will appear at all, or if it does appear, whether it will pass all the tests of efficacy and safety.




The timetable for a coronavirus vaccine is 18 months. Experts say that's risky

"It's absolutely essential that all societies everywhere get themselves into a position where they are able to defend against the coronavirus as a constant threat, and to be able to go about social life and economic activity with the virus in our midst," Nabarro tells CNN.
Most experts remain confident that a Covid-19 vaccine will eventually be developed; in part because, unlike previous diseases like HIV and malaria, the coronavirus does not mutate rapidly.
Many, including National Institute of Allergy and Infectious Diseases director Dr. Anthony Fauci, suggest it could happen in a year to 18 months. Other figures, like England's Chief Medical Officer Chris Whitty, have veered towards the more distant end of the spectrum, suggesting that a year may be too soon.
But even if a vaccine is developed, bringing it to fruition in any of those timeframes would be a feat never achieved before.
"We've never accelerated a vaccine in a year to 18 months," Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, tells CNN. "It doesn't mean it's impossible, but it will be quite a heroic achievement.
"We need plan A, and a plan B," he says.
When vaccines don't work
In 1984, the US Secretary of Health and Human Services Margaret Heckler announced at a press conference in Washington, DC, that scientists had successfully identified the virus that later became known as HIV -- and predicted that a preventative vaccine would be ready for testing in two years.
Nearly four decades and 32 million deaths later, the world is still waiting for an HIV vaccine.
Instead of a breakthrough, Heckler's claim was followed by the loss of much of a generation of gay men and the painful shunning of their community in Western countries. For many years, a positive diagnosis was not only a death sentence; it ensured a person would spend their final months abandoned by their communities, while doctors debated in medical journals whether HIV patients were even worth saving.



Protester Mark Milano is arrested during an AIDS demonstration in Washington DC in 1994.

The search didn't end in the 1980s. In 1997, President Bill Clinton challenged the US to come up with a vaccine within a decade. Fourteen years ago, scientists said we were still about 10 years away.
The difficulties in finding a vaccine began with the very nature of HIV/AIDS itself. "Influenza is able to change itself from one year to the next so the natural infection or immunization the previous year doesn't infect you the following year. HIV does that during a single infection," explains Paul Offit, a pediatrician and infectious disease specialist who co-invented the rotavirus vaccine.
"It continues to mutate in you, so it's like you're infected with a thousand different HIV strands," Offit tells CNN. "(And) while it is mutating, it's also crippling your immune system."
HIV poses very unique difficulties and Covid-19 does not possess its level of elusiveness, making experts generally more optimistic about finding a vaccine.




Lessons the AIDS epidemic has for coronavirus

But there have been other diseases that have confounded both scientists and the human body. An effective vaccine for dengue fever, which infects as many as 400,000 people a year according to the WHO, has eluded doctors for decades. In 2017, a large-scale effort to find one was suspended after it was found to worsen the symptoms of the disease.
Similarly, it's been very difficult to develop vaccines for the common rhinoviruses and adenoviruses -- which, like coronaviruses, can cause cold symptoms. There's just one vaccine to prevent two strains of adenovirus, and it's not commercially available.
"You have high hopes, and then your hopes are dashed," says Nabarro, describing the slow and painful process of developing a vaccine. "We're dealing with biological systems, we're not dealing with mechanical systems. It really depends so much on how the body reacts."
Human trials are already underway at Oxford University in England for a coronavirus vaccine made from a chimpanzee virus, and in the US for a different vaccine, produced by Moderna.
However, it is the testing process -- not the development -- that holds up and often scuppers the production of vaccines, adds Hotez, who worked on a vaccine to protect against SARS. "The hard part is showing you can prove that it works and it's safe."
Plan B
If the same fate befalls a Covid-19 vaccine, the virus could remain with us for many years. But the medical response to HIV/AIDS still provides a framework for living with a disease we can't stamp out.
"In HIV, we've been able to make that a chronic disease with antivirals. We've done what we've always hoped to do with cancer," Offit says. "It's not the death sentence it was in the 1980s."
The groundbreaking development of a daily preventative pill -- pre-exposure prophylaxis, or PrEP -- has since led to hundreds of thousands of people at risk of contracting HIV being protected from the disease.
A number of treatments are likewise being tested for Covid-19, as scientists hunt for a Plan B in parallel to the ongoing vaccine trials, but all of those trials are in very early stages. Scientists are looking at experimental anti-Ebola drug remdesivir, while blood plasma treatments are also being explored. Hydroxychloroquine, touted as a potential "game changer" by US President Donald Trump, has been found not to work on very sick patients.
"The drugs they've chosen are the best candidates," says Keith Neal, Emeritus Professor in the Epidemiology of Infectious Diseases at the University of Nottingham. The problem, he says, has been the "piecemeal approach" to testing them.



Remdesivir, one of the drugs being tested as a Covid-19 treatment.

"We have to do randomized controlled trials. It's ridiculous that only recently have we managed to get that off the ground," Neal, who reviews such tests for inclusion in medical journals, tells CNN. "The papers that I'm getting to look at -- I'm just rejecting them on the grounds that they're not properly done."
Now those fuller trials are off the ground, and if one of those drugs works for Covid-19 the signs should emerge "within weeks," says Neal. The first may already have arrived; the US Food and Drug Administration told CNN it is in talks to make remdesivir available to patients after positive signs it could speed up recovery from the coronavirus.
The knock-on effects of a successful treatment would be felt widely; if a drug can decrease a patient's average time spent in ICU even by by a few days, it would free up hospital capacity and could therefore greatly increase the willingness of governments to open up society.
But how effective a treatment is would depend on which one works -- remdesivir is not in high supply internationally and scaling up its production would cause problems.
And crucially, any treatment won't prevent infections occurring in society -- meaning the coronavirus would be easier to manage and the pandemic would subside, but the disease could be with us many years into the future.
What life without a vaccine looks like
If a vaccine can't be produced, life will not remain as it is now. It just might not go back to normal quickly.
"The lockdown is not sustainable economically, and possibly not politically," says Neal. "So we need other things to control it."
That means that, as countries start to creep out of their paralyses, experts would push governments to implement an awkward new way of living and interacting to buy the world time in the months, years or decades until Covid-19 can be eliminated by a vaccine.
"It is absolutely essential to work on being Covid-ready," Nabarro says. He calls for a new "social contract" in which citizens in every country, while starting to go about their normal lives, take personal responsibility to self-isolate if they show symptoms or come into contact with a potential Covid-19 case.



Social distancing and lockdowns could be reintroduced until a vaccine is found.

It means the culture of shrugging off a cough or light cold symptoms and trudging into work should be over. Experts also predict a permanent change in attitudes towards remote working, with working from home, at least on some days, becoming a standard way of life for white collar employees. Companies would be expected to shift their rotas so that offices are never full unnecessarily.
"It (must) become a way of behaving that we all ascribe to personal responsibility ... treating those who are isolated as heroes rather than pariahs," says Nabarro. "A collective pact for survival and well-being in the face of the threat of the virus.
"It's going to be difficult to do in poorer nations," he adds, so finding ways to support developing countries will become "particularly politically tricky, but also very important." He cites tightly packed refugee and migrant settlements as areas of especially high concern.
In the short term, Nabarro says a vast program of testing and contact tracing would need to be implemented to allow life to function alongside Covid-19 -- one which dwarfs any such program ever established to fight an outbreak, and which remains some time away in major countries like the US and the UK.
"Absolutely critical is going to be having a public health system in place that includes contact tracing, diagnosis in the workplace, monitoring for syndromic surveillance, early communication on whether we have to re-implement social distancing," adds Hotez. "It's doable, but it's complicated and we really haven't done it before."




America's 'new normal' will be anything but ordinary

Those systems could allow for some social interactions to return. "If there's minimal transmission, it may indeed be possible to open things up for sporting events" and other large gatherings, says Hotez -- but such a move would not be permanent and would continually be assessed by governments and public health bodies.
That means the the Premier League, NFL and other mass events could go ahead with their schedules as long as athletes are getting regularly tested, and welcome in fans for weeks at a time -- perhaps separated within the stands -- before quickly shutting stadiums if the threat rises.
"Bars and pubs are probably last on the list as well, because they are overcrowded," suggests Neal. "They could reopen as restaurants, with social distancing." Some European countries have signaled they will start allowing restaurants to serve customers at vastly reduced capacity.
Restrictions are most likely to come back over the winter, with Hotez suggesting that Covid-19 peaks could occur every winter until a vaccine is introduced.
And lockdowns, many of which are in the process of gradually being lifted, could return at any moment. "From time to time there will be outbreaks, movement will be restricted -- and that may apply to parts of a country, or it may even apply to a whole country," Nabarro says.

Related coverage

Oxford partners with pharma giant to develop vaccine Coronavirus is changing some anti-vaxxers' minds Wuhan shows the world that normal is still some time away

The more time passes, the more imposing becomes the hotly debated prospect of herd immunity -- reached when the majority of a given population, around 70% to 90%, becomes immune to an infectious disease. "That does to some extent limit spread," Offit says -- "although population immunity caused by natural infection is not the best way to provide population immunity. The best way is with a vaccine."
Measles is the "perfect example," says Offit -- before vaccines became widespread, "every year 2 to 3 million people would get measles, and that would be true here too." In other words, the amount of death and suffering from Covid-19 would be vast even if a large portion of the population is not susceptible.

All of these predictions are tempered by a general belief that a vaccine will, eventually, be developed. "I do think there'll be vaccine -- there's plenty of money, there's plenty of interest and the target is clear," Offit says.
But if previous outbreaks have proven anything, it's that hunts for vaccines are unpredictable. "I don't think any vaccine has been developed quickly," Offit cautions. "I'd be really amazed if we had something in 18 months."